US Oncology Reports Second Quarter Operating Results

...July 30, 2008, the United States Food and Drug Administration ("FDA") published a final new label for Erythropoiesis-Stimulating Agents ("ESAs") drugs aranesp and Procrit. This action was taken contemporaneously to the previous national coverage decision ("NCD") by the Centers for Medicare and Medicaid Serv...

Nephrologists Indicate High Interest in AMAG Pharmaceuticals' Newly Approved Feraheme According to Latest BioTrends Report

...-ND) market as well. This adds importance to Nephrologists' perception that Centocor-Ortho Biotech's Procrit has a competitive advantage over Amgen's aranesp on "minimal hassles with prior authorizations" and "adequate reimbursement". In the phosphate binder market, Genzyme's sevelamer compounds are...

Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29

...n during the second quarter of 2008. In the U.S., aranesp sales decreased 21 percent to $338 million in the ...sser extent, loss of segment share. International aranesp sales decreased 11 percent to $355 million in the ...xcluding the impact of foreign exchange, worldwide aranesp product sales decreased 11 percent and internation...

Amgen Highlights Data to Be Presented at ASCO

...2 (Sunday, May 31, 2009, 8:00am-12:00pm) aranesp (R) (darbepoetin alfa) Final data from the DAHANCA-10 aranesp pharmacovigilance trial in head and neck cancer pa...py, with the exception of bone pain. About aranesp ...

Product Shifts are Occurring in the Renal Anemia and Bone and Mineral Metabolism Markets According to the Most Recent TreatmentTrends(R): US Nephrology Report from BioTrends Research Group

...he expense of Amgen's Aranesp. And while only about one-third of Nephrologists report that managed care policies have led to a decreased use of ESAs, aranesp seems to be more negatively impacted by managed care than Procrit. There have been no significant changes in the use of IV iron in the past year...

Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08

...on during the first quarter of 2008. In the U.S., aranesp sales decreased 28 percent to $292 million in the ...ese changes in accounting estimates, U.S. sales of aranesp declined 21 percent in the first quarter of 2009. ...e changes in wholesaler inventories. International aranesp sales decreased 6 percent to $334 million versus $...

US Oncology Reports Fourth Quarter and Yearend 2008 Results

...July 30, 2008, the United States Food and Drug Administration ("FDA") published a final new label for Erythropoiesis-Stimulating Agents ("ESAs") drugs aranesp and Procrit. This action was taken contemporaneously to the previous national coverage decision ("NCD") by the Centers for Medicare and Medicaid Serv...

New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists

... renal anemia and hyperphosphatemia. In the anemia market, Amgen's aranesp is the market share leader among patients with Chronic Kidney Disease not on dialysis (CKD) whereas share between aranesp and Eprex in the dialysis market is more evenly divided. Satisfaction betw...

US Oncology Reports Third Quarter 2008 Results

...July 30, 2008, the United States Food and Drug Administration ("FDA") published a final new label for Erythropoiesis-Stimulating Agents ("ESAs") drugs aranesp and Procrit. This action was taken contemporaneously to the previous national coverage decision ("NCD") by the Centers for Medicare and Medicaid Servi...

Anemia Drugs May Speed Tumor Growth in Some Cancer Patients

...ociety of Clinical Oncology annual meeting in Chicago. Recent controversy over erythropoiesis-stimulating agents (ESAs) such as Procrit, Epogen and aranesp has centered around whether the blood-boosting drugs should be withdrawn from the market because of troubling side effects. In March, a U.S. Food a...

Aranesp in Medical Technology

Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting

...ng chemotherapy or radiotherapy ("the 103 study"). aranesp is not approved for use by the FDA or EMEA in thes...Transfusion occurrences from weeks 5 to 17 favored aranesp but were not statistically significant between the...r, the overall number of deaths was greater in the aranesp group (48.5 percent versus 46 percent in placebo; ...

Aranesp ``145 Study'' Shows No Difference in Survival in Patients with Small-Cell Lung Cancer

...cant difference in risk of death (overall survival aranesp compared to placebo Hazard Ratio (HR): 0.93, 95% C...hemoglobin concentration from baseline in favor of aranesp (a co-primary endpoint). Aranesp-treated patients ...lable for replay 72 hours after the event. About aranesp ...

Aranesp in Biological Technology

Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55

...n during the fourth quarter of 2007. In the U.S., aranesp sales decreased 22 percent to $361 million in the ...lion in the fourth quarter of 2007. U.S. sales of aranesp for the fourth quarter of 2007 benefited $37 milli...ese changes in accounting estimates, U.S. sales of aranesp decreased 15 percent in the fourth quarter of 2008...

BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...ation of new ESAs could also alter market dynamics in which Amgen's Epogen currently leads the dialysis market and Ortho Biotech's Procrit and Amgen's aranesp virtually split the CKD market. Even though the perceived need for new ESA therapies is relatively low, ESAs with extended dosing intervals are desir...

European Nephrologists Share Insights on the Management of Renal Anemia and Hyperphosphatemia in Latest BioTrends Report

...rphosphatemia. In the ESA market, Amgen's aranesp is the market share leader in both dialysis and CK...re loss coming from Roche's NeoRecormon. Although aranesp is expected to see share decreases in almost all markets, Nephrologists project aranesp will maintain its market leader position in both d...

BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...e of ESAs in CKD or dialysis. While Amgen's Epogen continues to dominate the dialysis market, there did seem to be some brand shifting between Amgen's aranesp and Ortho Biotech's Procrit in CKD. Nephrologists do not predict significant changes in ESA market share in CKD or dialysis in the near-term, but they...

Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23

...d quarter of 2007. In the U.S., third quarter 2008 aranesp sales were relatively unchanged at $458 million in...illion in the third quarter of 2007. U.S. sales of aranesp in the third quarter of 2008 benefited from a $54 ...of 2008 versus the prior year. The decline in U.S. aranesp sales reflects the negative impact on demand, prim...

CBDM.T, The Market and Business Intelligence Company Reviews The Biomanufacturing Market

...m Novo Nordisk is still the 9th in the top 10 biotech drugs sold in the US. The top 5 leading biotech drugs sold in the USA are Enbrel (Amgen, Wyeth), aranesp (Amgen), Rituxan (Biogen Idec, Genentech, Roche), Remicade (Johnson & Johnson, Schering-Plough) and Procrit (Johnson and Johnson). According t...

New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices

...pically driven by geography or insurance. From a brand perspective, Amgen's aranesp and Ortho-Biotech's Procrit continue to battle for market leadership in CKD...e on tolerability, ease of dosing modifications, and reimbursement, whereas aranesp has an advantage for patients who self-inject. IV iron is used with much le...

BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...en no significant changes in market share year over year (Amgen's Epogen remains the market leader in dialysis and Ortho Biotech's Procrit and Amgen's aranesp continue to battle for market leader position in CKD), there are indicators of brand switching, particularly related to office stocking and managed ca...

New Study by BioTrends Highlights Practice Management Shifts Among European Nephrologists

...osphatemia, and secondary hyperparathyroidism. In the ESA market, Amgen's aranesp is the market share leader in pre-dialysis and is competing vigorously agai...lysis. An attribute analysis details significant competitive advantages for aranesp with regard to ease of administration and extended dosing intervals, while ...

BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...enal related product initiated in CKD. While Nephrologists perceive Amgen's aranesp and Ortho Biotech's Procrit to be very similar, there are significant diffe... product with Procrit claiming an advantage in safety and reimbursement and aranesp claiming an advantage in dosing intervals. The two continue to battle for m...